cd19 chimeric antigen receptor t-cells + cd20 chimeric antigen receptor t-cells

The combination of CD19-targeted and CD20-targeted chimeric antigen receptor (CAR) T-cells represents a second-generation approach to B-cell malignancy immunotherapy. While early CAR-T therapies focused exclusively on the B-lymphocyte antigen CD19, clinical experience revealed that many patients relapsed due to 'antigen escape,' where tumor cells downregulate or lose CD19 expression to evade the immune system. By incorporating a second target—the B-lymphocyte antigen CD20—developers aim to provide a redundant mechanism of action that maintains therapeutic pressure even if one antigen is lost. This strategy is currently being investigated using two primary formats: a 'cocktail' approach involving the co-administration of two separate CAR-T products, and 'bispecific' CAR-T cells, where a single T-cell population expresses CARs containing both CD19 and CD20 binding domains in tandem or loop configurations. Key developers include Carsgen, Mustang Bio, and Miltenyi Biotec, with clinical investigations targeting refractory B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

Other names

CD19/CD20 dual-targeted CAR-T cellsCD19-CD20 bispecific CAR-T cellsCD-19-CD20 bispecific CAR-T cellsCD 19-CD20 bispecific CAR-T cellsCD19+CD20 CAR-T cocktailCD19/CD20 dual-antigen CAR-T cells